Tezepelumab

Tezepelumab
	Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	thymic stromal lymphopoietin (TSLP)
Clinical data
Trade names	Tezspire
Other names	MEDI9929, AMG 157, tezepelumab-ekko
AHFS/Drugs.com	Monograph
MedlinePlus	a622010
License data	US DailyMed: Tezepelumab;
Routes of; administration	Subcutaneous
ATC code	R03DX11 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1572943-04-4;
DrugBank	DB15090;
ChemSpider	None;
UNII	RJ1IW3B4QX;
KEGG	D11771;
Chemical and physical data
Formula	C6400H9844N1732O1992S52
Molar mass	144590.40 g·mol−1

Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma. Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

The most common side effects include arthralgia (joint pain) and pharyngitis (sore throat).

Tezepelumab was approved for medical use in the United States in December 2021, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.